Literature DB >> 1287034

Immunological studies in the hyper-immunoglobulin D syndrome.

A Haraldsson1, C M Weemaes, A W De Boer, J A Bakkeren, G B Stoelinga.   

Abstract

Five patients with hyper-immunoglobulin D syndrome (hyper-IgD syndrome) were followed up for 3 to 8 years. In all patients studied, serum IgG3 was high. IgM decreased during the follow-up in all patients. In four of the patients serum IgA was elevated. In four patients the serum IgD kappa/lambda ratio was measured and was found to be raised in all. However, the serum total light-chain ratio and IgG, IgA, and IgM kappa/lambda ratios separately were virtually normal. In two of the patients, clinical symptoms preceded the increase in serum IgD. All patients had a history of severe reactions on immunizations in early childhood. We conclude that in hyper-IgD syndrome, other immunoglobulins may also be affected, in particular, IgA, IgM, and IgG3. The IgD light-chain ratio is also disturbed. We emphasize that clinical symptoms may herald immunological changes. This may be the result of an underlying factor causing both the clinical symptoms and, later, the increasing serum IgD levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287034     DOI: 10.1007/bf00918854

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  17 in total

1.  Determination of kappa and lambda light chains in serum immunoglobulins G, A and M.

Authors:  A Haraldsson; M J Kock-Jansen; M Jaminon; P B van Eck-Arts; T de Boo; C M Weemaes; J A Bakkeren
Journal:  Ann Clin Biochem       Date:  1991-09       Impact factor: 2.057

2.  T cells with receptors for IgD.

Authors:  R F Coico; B Xue; D Wallace; B Pernis; G W Siskind; G J Thorbecke
Journal:  Nature       Date:  1985 Aug 22-28       Impact factor: 49.962

3.  Hyperimmunoglobulinaemia D and periodic fever: a new syndrome.

Authors:  J W van der Meer; J M Vossen; J Radl; J A van Nieuwkoop; C J Meyer; S Lobatto; R van Furth
Journal:  Lancet       Date:  1984-05-19       Impact factor: 79.321

4.  The molecular biology of immunoglobulin D.

Authors:  F R Blattner; P W Tucker
Journal:  Nature       Date:  1984 Feb 2-8       Impact factor: 49.962

5.  Thyroid-stimulating autoantibodies usually contain only lambda-light chains: evidence for the "forbidden clone" theory.

Authors:  J Knight; P Laing; A Knight; D Adams; N Ling
Journal:  J Clin Endocrinol Metab       Date:  1986-02       Impact factor: 5.958

6.  Enzyme-linked immunosorbent assay (ELISA) screening test for detection of rheumatoid factor.

Authors:  T Jonsson; J A Arnason; H Valdimarsson
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

7.  [On the isolation and determination of immunoglobulin-A (IgA)].

Authors:  P J van Munster; G B Stoelinga
Journal:  Maandschr Kindergeneeskd       Date:  1965-11

8.  Light chain types of IgD in human bone marrow and serum.

Authors:  J A van Nieuwkoop; J Radl
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

9.  Characterization of IgD. I. Isolation of two molecular forms from human serum.

Authors:  G Corte; P Tonda; E Cosulich; C P Milstein; A Bargellesi; M Ferrarini
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

10.  Immunoglobulin G, A, and M light chain ratios in some humoral immunological disorders.

Authors:  A Haraldsson; M Jaminon; J A Bakkeren; G B Stoelinga; C M Weemaes
Journal:  Scand J Immunol       Date:  1992-07       Impact factor: 3.487

View more
  8 in total

Review 1.  Immunoglobulin D: properties, measurement, and clinical relevance.

Authors:  A O Vladutiu
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Hyper-IgD and periodic fever syndrome (HIDS) due to compound heterozygosity for G336S and V377I in a 44-year-old patient with a 27-year history of fever.

Authors:  Stefan Schlabe; Carolynne Schwarze-Zander; Peter Lohse; Jürgen Kurt Rockstroh
Journal:  BMJ Case Rep       Date:  2016-11-29

3.  Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells.

Authors:  J P Drenth; J Göertz; M R Daha; J W van der Meer
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

4.  Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome.

Authors:  I S Klasen; J H Göertz; G A van de Wiel; C M Weemaes; J W van der Meer; J P Drenth
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

5.  The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.

Authors:  Micol Romano; Z Serap Arici; David Piskin; Sara Alehashemi; Daniel Aletaha; Karyl Barron; Susanne Benseler; Roberta A Berard; Lori Broderick; Fatma Dedeoglu; Michelle Diebold; Karen Durrant; Polly Ferguson; Dirk Foell; Jonathan S Hausmann; Olcay Y Jones; Daniel Kastner; Helen J Lachmann; Ronald M Laxer; Dorelia Rivera; Nicola Ruperto; Anna Simon; Marinka Twilt; Joost Frenkel; Hal M Hoffman; Adriana A de Jesus; Jasmin B Kuemmerle-Deschner; Seza Ozen; Marco Gattorno; Raphaela Goldbach-Mansky; Erkan Demirkaya
Journal:  Arthritis Rheumatol       Date:  2022-05-27       Impact factor: 15.483

6.  An Atypical Presentation of Mevalonate Kinase Deficiency in Response to Colchicine Treatment.

Authors:  Merve Koç Yekedüz; Neslihan Doğulu; Ümmühan Öncül; Engin Köse; Serdar Ceylaner; Fatma Tuba Eminoğlu
Journal:  Mol Syndromol       Date:  2021-10-25

Review 7.  Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome.

Authors:  Dorothea Haas; Georg F Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2006-04-26       Impact factor: 4.123

8.  B cell cytopenia in two brothers with hyper-IgD and periodic fever syndrome.

Authors:  M Sornsakrin; K Wenner; R Ganschow
Journal:  Eur J Pediatr       Date:  2008-10-07       Impact factor: 3.860

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.